Cited by — First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.
No admitted local citation edges point to this work yet.
